TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2015 DA - 2015// TI - Cancer statistics, 2015 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21254 DO - 10.3322/caac.21254 ID - Siegel2015 ER - TY - JOUR AU - Schorge, J. O. AU - Modesitt, S. C. AU - Coleman, R. L. AU - Cohn, D. E. AU - Kauff, N. D. AU - Duska, L. R. PY - 2010 DA - 2010// TI - SGO white paper on ovarian cancer: etiology, screening and surveillance JO - Gynecol Oncol VL - 119 UR - https://doi.org/10.1016/j.ygyno.2010.06.003 DO - 10.1016/j.ygyno.2010.06.003 ID - Schorge2010 ER - TY - JOUR AU - Schorge, J. O. AU - Bradford, L. S. AU - Carmen, M. G. PY - 2011 DA - 2011// TI - Primary cytoreductive surgery for advanced ovarian cancer: is it the past, present, or future? JO - Clin Adv Hematol Oncol VL - 9 ID - Schorge2011 ER - TY - JOUR AU - Ozols, R. F. AU - Bundy, B. N. AU - Greer, B. E. AU - Fowler, J. M. AU - Clarke-Pearson, D. AU - Burger, R. A. PY - 2003 DA - 2003// TI - Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.02.153 DO - 10.1200/JCO.2003.02.153 ID - Ozols2003 ER - TY - JOUR AU - Armstrong, D. K. AU - Bundy, B. AU - Wenzel, L. AU - Huang, H. Q. AU - Baergen, R. AU - Lele, S. PY - 2006 DA - 2006// TI - Intraperitoneal cisplatin and paclitaxel in ovarian cancer JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMoa052985 DO - 10.1056/NEJMoa052985 ID - Armstrong2006 ER - TY - JOUR AU - Growdon, W. B. AU - Birrer, M. J. AU - Penson, R. T. PY - 2010 DA - 2010// TI - Ovarian cancer: individualized and personalized care JO - Expert Rev Obstet Gynecol VL - 5 UR - https://doi.org/10.1586/eog.10.35 DO - 10.1586/eog.10.35 ID - Growdon2010 ER - TY - JOUR AU - Al-Janadi, A. AU - Chandana, S. R. AU - Conley, B. A. PY - 2008 DA - 2008// TI - Histone deacetylation: an attractive target for cancer therapy? JO - Drugs R D VL - 9 UR - https://doi.org/10.2165/0126839-200809060-00003 DO - 10.2165/0126839-200809060-00003 ID - Al-Janadi2008 ER - TY - JOUR AU - Kwon, M. J. AU - Shin, Y. K. PY - 2011 DA - 2011// TI - Epigenetic regulation of cancer-associated genes in ovarian cancer JO - Int J Mol Sci VL - 12 UR - https://doi.org/10.3390/ijms12020983 DO - 10.3390/ijms12020983 ID - Kwon2011 ER - TY - JOUR AU - Maradeo, M. E. AU - Cairns, P. PY - 2011 DA - 2011// TI - Translational application of epigenetic alterations: ovarian cancer as a model JO - FEBS Lett VL - 585 UR - https://doi.org/10.1016/j.febslet.2011.03.016 DO - 10.1016/j.febslet.2011.03.016 ID - Maradeo2011 ER - TY - JOUR AU - Lane, A. A. AU - Chabner, B. A. PY - 2009 DA - 2009// TI - Histone deacetylase inhibitors in cancer therapy JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.22.1291 DO - 10.1200/JCO.2009.22.1291 ID - Lane2009 ER - TY - JOUR AU - Gregory, P. D. AU - Wagner, K. AU - Horz, W. PY - 2001 DA - 2001// TI - Histone acetylation and chromatin remodeling JO - Exp Cell Res VL - 265 UR - https://doi.org/10.1006/excr.2001.5187 DO - 10.1006/excr.2001.5187 ID - Gregory2001 ER - TY - JOUR AU - Strahl, B. D. AU - Allis, C. D. PY - 2000 DA - 2000// TI - The language of covalent histone modifications JO - Nature VL - 403 UR - https://doi.org/10.1038/47412 DO - 10.1038/47412 ID - Strahl2000 ER - TY - JOUR AU - Frew, A. J. AU - Johnstone, R. W. AU - Bolden, J. E. PY - 2009 DA - 2009// TI - Enhancing the apoptotic and therapeutic effects of HDAC inhibitors JO - Cancer Lett VL - 280 UR - https://doi.org/10.1016/j.canlet.2009.02.042 DO - 10.1016/j.canlet.2009.02.042 ID - Frew2009 ER - TY - JOUR AU - Camphausen, K. AU - Tofilon, P. J. PY - 2007 DA - 2007// TI - Inhibition of histone deacetylation: a strategy for tumor radiosensitization JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.11.6202 DO - 10.1200/JCO.2007.11.6202 ID - Camphausen2007 ER - TY - JOUR AU - Park, J. H. AU - Jong, H. S. AU - Kim, S. G. AU - Jung, Y. AU - Lee, K. W. AU - Lee, J. H. PY - 2008 DA - 2008// TI - Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase JO - J Mol Med (Berl) VL - 86 UR - https://doi.org/10.1007/s00109-007-0260-8 DO - 10.1007/s00109-007-0260-8 ID - Park2008 ER - TY - JOUR AU - Takai, N. AU - Narahara, H. PY - 2007 DA - 2007// TI - Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis JO - Curr Med Chem VL - 14 UR - https://doi.org/10.2174/092986707782023299 DO - 10.2174/092986707782023299 ID - Takai2007 ER - TY - JOUR AU - Singh, B. N. AU - Zhou, H. AU - Li, J. AU - Tipton, T. AU - Wang, B. AU - Shao, G. PY - 2011 DA - 2011// TI - Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers JO - Future Oncol VL - 7 UR - https://doi.org/10.2217/fon.11.124 DO - 10.2217/fon.11.124 ID - Singh2011 ER - TY - JOUR AU - Budman, D. R. AU - Tai, J. AU - Calabro, A. AU - John, V. PY - 2011 DA - 2011// TI - The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines JO - Invest New Drugs VL - 29 UR - https://doi.org/10.1007/s10637-010-9467-6 DO - 10.1007/s10637-010-9467-6 ID - Budman2011 ER - TY - JOUR AU - Chen, X. AU - Wong, P. AU - Radany, E. AU - Wong, J. Y. PY - 2009 DA - 2009// TI - HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells JO - Cancer Biother Radiopharm VL - 24 UR - https://doi.org/10.1089/cbr.2009.0629 DO - 10.1089/cbr.2009.0629 ID - Chen2009 ER - TY - JOUR AU - LaBonte, M. J. AU - Wilson, P. M. AU - Fazzone, W. AU - Groshen, S. AU - Lenz, H. J. AU - Ladner, R. D. PY - 2009 DA - 2009// TI - DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines JO - BMC Med Genet VL - 2 ID - LaBonte2009 ER - TY - JOUR AU - Cooper, A. L. AU - Greenberg, V. L. AU - Lancaster, P. S. AU - Nagell, J. R. AU - Zimmer, S. G. AU - Modesitt, S. C. PY - 2007 DA - 2007// TI - In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer JO - Gynecol Oncol VL - 104 UR - https://doi.org/10.1016/j.ygyno.2006.09.011 DO - 10.1016/j.ygyno.2006.09.011 ID - Cooper2007 ER - TY - JOUR AU - Modesitt, S. C. AU - Parsons, S. J. PY - 2010 DA - 2010// TI - In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter? JO - Gynecol Oncol VL - 119 UR - https://doi.org/10.1016/j.ygyno.2010.06.030 DO - 10.1016/j.ygyno.2010.06.030 ID - Modesitt2010 ER - TY - JOUR AU - Marchion, D. AU - Munster, P. PY - 2007 DA - 2007// TI - Development of histone deacetylase inhibitors for cancer treatment JO - Expert Rev Anticancer Ther VL - 7 UR - https://doi.org/10.1586/14737140.7.4.583 DO - 10.1586/14737140.7.4.583 ID - Marchion2007 ER - TY - JOUR AU - Qiu, T. AU - Zhou, L. AU - Zhu, W. AU - Wang, T. AU - Wang, J. AU - Shu, Y. PY - 2013 DA - 2013// TI - Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials JO - Future Oncol VL - 9 UR - https://doi.org/10.2217/fon.12.173 DO - 10.2217/fon.12.173 ID - Qiu2013 ER - TY - JOUR AU - Liu, Z. AU - Tong, Y. AU - Liu, Y. AU - Liu, H. AU - Li, C. AU - Zhao, Y. PY - 2014 DA - 2014// TI - Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms JO - Cancer Cell Int VL - 14 ID - Liu2014 ER - TY - JOUR AU - Marks, P. A. AU - Dokmanovic, M. PY - 2005 DA - 2005// TI - Histone deacetylase inhibitors: discovery and development as anticancer agents JO - Expert Opin Investig Drugs VL - 14 UR - https://doi.org/10.1517/13543784.14.12.1497 DO - 10.1517/13543784.14.12.1497 ID - Marks2005 ER - TY - JOUR AU - Fukutomi, A. AU - Hatake, K. AU - Matsui, K. AU - Sakajiri, S. AU - Hirashima, T. AU - Tanii, H. PY - 2012 DA - 2012// TI - A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors JO - Invest New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-011-9666-9 DO - 10.1007/s10637-011-9666-9 ID - Fukutomi2012 ER - TY - JOUR AU - Hainsworth, J. D. AU - Infante, J. R. AU - Spigel, D. R. AU - Arrowsmith, E. R. AU - Boccia, R. V. AU - Burris, H. A. PY - 2011 DA - 2011// TI - A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma JO - Cancer Invest VL - 29 UR - https://doi.org/10.3109/07357907.2011.590568 DO - 10.3109/07357907.2011.590568 ID - Hainsworth2011 ER - TY - JOUR AU - Glaser, K. B. PY - 2007 DA - 2007// TI - HDAC inhibitors: clinical update and mechanism-based potential JO - Biochem Pharmacol VL - 74 UR - https://doi.org/10.1016/j.bcp.2007.04.007 DO - 10.1016/j.bcp.2007.04.007 ID - Glaser2007 ER - TY - JOUR AU - Batty, N. AU - Malouf, G. G. AU - Issa, J. P. PY - 2009 DA - 2009// TI - Histone deacetylase inhibitors as anti-neoplastic agents JO - Cancer Lett VL - 280 UR - https://doi.org/10.1016/j.canlet.2009.03.013 DO - 10.1016/j.canlet.2009.03.013 ID - Batty2009 ER - TY - JOUR AU - Jones, S. F. AU - Bendell, J. C. AU - Infante, J. R. AU - Spigel, D. R. AU - Thompson, D. S. AU - Yardley, D. A. PY - 2011 DA - 2011// TI - A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors JO - Clin Adv Hematol Oncol VL - 9 ID - Jones2011 ER - TY - JOUR AU - Matulonis, U. AU - Berlin, S. AU - Lee, H. AU - Whalen, C. AU - Obermayer, E. AU - Penson, R. PY - 2015 DA - 2015// TI - Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer JO - Cancer Chemother Pharmacol VL - 76 UR - https://doi.org/10.1007/s00280-015-2813-9 DO - 10.1007/s00280-015-2813-9 ID - Matulonis2015 ER - TY - STD TI - Wang C, Chen J, Cao W, Sun L, Sun H, Liu Y. Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways. Eur J Pharmacol. 2016;779:1–7. ID - ref33 ER - TY - JOUR AU - Fu, J. AU - Bian, M. AU - Jiang, Q. AU - Zhang, C. PY - 2007 DA - 2007// TI - Roles of Aurora kinases in mitosis and tumorigenesis JO - Mol Cancer Res VL - 5 UR - https://doi.org/10.1158/1541-7786.MCR-06-0208 DO - 10.1158/1541-7786.MCR-06-0208 ID - Fu2007 ER - TY - JOUR AU - Warner, S. L. AU - Bearss, D. J. AU - Han, H. AU - Hoff, D. D. PY - 2003 DA - 2003// TI - Targeting Aurora-2 kinase in cancer JO - Mol Cancer Ther VL - 2 UR - https://doi.org/10.4161/cbt.2.5.506 DO - 10.4161/cbt.2.5.506 ID - Warner2003 ER - TY - JOUR AU - Doggrell, S. A. PY - 2004 DA - 2004// TI - Dawn of Aurora kinase inhibitors as anticancer drugs JO - Expert Opin Investig Drugs VL - 13 UR - https://doi.org/10.1517/13543784.13.9.1199 DO - 10.1517/13543784.13.9.1199 ID - Doggrell2004 ER - TY - JOUR AU - Sen, S. AU - Zhou, H. AU - Zhang, R. D. AU - Yoon, D. S. AU - Vakar-Lopez, F. AU - Ito, S. PY - 2002 DA - 2002// TI - Amplification/overexpression of a mitotic kinase gene in human bladder cancer JO - J Natl Cancer Inst VL - 94 UR - https://doi.org/10.1093/jnci/94.17.1320 DO - 10.1093/jnci/94.17.1320 ID - Sen2002 ER - TY - JOUR AU - Aust, D. E. AU - Muders, M. AU - Kohler, A. AU - Schmidt, M. AU - Diebold, J. AU - Muller, C. PY - 2004 DA - 2004// TI - Prognostic relevance of 20q13 gains in sporadic colorectal cancers: a FISH analysis JO - Scand J Gastroenterol VL - 39 UR - https://doi.org/10.1080/00365520410003191 DO - 10.1080/00365520410003191 ID - Aust2004 ER - TY - JOUR AU - Keen, N. AU - Taylor, S. PY - 2004 DA - 2004// TI - Aurora-kinase inhibitors as anticancer agents JO - Nat Rev Cancer VL - 4 UR - https://doi.org/10.1038/nrc1502 DO - 10.1038/nrc1502 ID - Keen2004 ER - TY - JOUR AU - Hu, W. AU - Kavanagh, J. J. AU - Deaver, M. AU - Johnston, D. A. AU - Freedman, R. S. AU - Verschraegen, C. F. PY - 2005 DA - 2005// TI - Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer JO - Oncol Res VL - 15 ID - Hu2005 ER - TY - JOUR AU - Landen, C. N. AU - Lin, Y. G. AU - Immaneni, A. AU - Deavers, M. T. AU - Merritt, W. M. AU - Spannuth, W. A. PY - 2007 DA - 2007// TI - Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-0431 DO - 10.1158/1078-0432.CCR-07-0431 ID - Landen2007 ER - TY - JOUR AU - Anand, S. AU - Penrhyn-Lowe, S. AU - Venkitaraman, A. R. PY - 2003 DA - 2003// TI - AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol JO - Cancer Cell VL - 3 UR - https://doi.org/10.1016/S1535-6108(02)00235-0 DO - 10.1016/S1535-6108(02)00235-0 ID - Anand2003 ER - TY - JOUR AU - Li, Y. AU - Liu, T. AU - Ivan, C. AU - Huang, J. AU - Shen, D. Y. AU - Kavanagh, J. J. PY - 2013 DA - 2013// TI - Enhanced cytotoxic effects of combined valproic acid and the aurora kinase inhibitor VE465 on gynecologic cancer cells JO - Front Oncol VL - 3 ID - Li2013 ER - TY - JOUR AU - Duan, Z. AU - Lamendola, D. E. AU - Duan, Y. AU - Yusuf, R. Z. AU - Seiden, M. V. PY - 2005 DA - 2005// TI - Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines JO - Cancer Chemother Pharmacol VL - 55 UR - https://doi.org/10.1007/s00280-004-0878-y DO - 10.1007/s00280-004-0878-y ID - Duan2005 ER - TY - JOUR AU - Meerloo, J. AU - Kaspers, G. J. AU - Cloos, J. PY - 2011 DA - 2011// TI - Cell sensitivity assays: the MTT assay JO - Methods Mol Biol VL - 731 UR - https://doi.org/10.1007/978-1-61779-080-5_20 DO - 10.1007/978-1-61779-080-5_20 ID - Meerloo2011 ER - TY - JOUR AU - Curley, M. D. AU - Therrien, V. A. AU - Cummings, C. L. AU - Sergent, P. A. AU - Koulouris, C. R. AU - Friel, A. M. PY - 2009 DA - 2009// TI - CD133 expression defines a tumor initiating cell population in primary human ovarian cancer JO - Stem Cells VL - 27 ID - Curley2009 ER - TY - JOUR AU - Arts, J. AU - Angibaud, P. AU - Marien, A. AU - Floren, W. AU - Janssens, B. AU - King, P. PY - 2007 DA - 2007// TI - R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies JO - Br J Cancer VL - 97 UR - https://doi.org/10.1038/sj.bjc.6604025 DO - 10.1038/sj.bjc.6604025 ID - Arts2007 ER - TY - JOUR AU - Zhang, Y. AU - Li, N. AU - Caron, C. AU - Matthias, G. AU - Hess, D. AU - Khochbin, S. PY - 2003 DA - 2003// TI - HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo JO - EMBO J VL - 22 UR - https://doi.org/10.1093/emboj/cdg115 DO - 10.1093/emboj/cdg115 ID - Zhang2003 ER - TY - JOUR AU - Nakagawa, M. AU - Oda, Y. AU - Eguchi, T. AU - Aishima, S. AU - Yao, T. AU - Hosoi, F. PY - 2007 DA - 2007// TI - Expression profile of class I histone deacetylases in human cancer tissues JO - Oncol Rep VL - 18 ID - Nakagawa2007 ER - TY - JOUR AU - Yoo, C. B. AU - Jones, P. A. PY - 2006 DA - 2006// TI - Epigenetic therapy of cancer: past, present and future JO - Nat Rev Drug Discov VL - 5 UR - https://doi.org/10.1038/nrd1930 DO - 10.1038/nrd1930 ID - Yoo2006 ER - TY - JOUR AU - Gu, W. AU - Roeder, R. G. PY - 1997 DA - 1997// TI - Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain JO - Cell VL - 90 UR - https://doi.org/10.1016/S0092-8674(00)80521-8 DO - 10.1016/S0092-8674(00)80521-8 ID - Gu1997 ER - TY - JOUR AU - Kovacs, J. J. AU - Murphy, P. J. AU - Gaillard, S. AU - Zhao, X. AU - Wu, J. T. AU - Nicchitta, C. V. PY - 2005 DA - 2005// TI - HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor JO - Mol Cell VL - 18 UR - https://doi.org/10.1016/j.molcel.2005.04.021 DO - 10.1016/j.molcel.2005.04.021 ID - Kovacs2005 ER - TY - JOUR AU - Weichert, W. PY - 2009 DA - 2009// TI - HDAC expression and clinical prognosis in human malignancies JO - Cancer Lett VL - 280 UR - https://doi.org/10.1016/j.canlet.2008.10.047 DO - 10.1016/j.canlet.2008.10.047 ID - Weichert2009 ER - TY - JOUR AU - Qian, D. Z. AU - Kato, Y. AU - Shabbeer, S. AU - Wei, Y. AU - Verheul, H. M. AU - Salumbides, B. PY - 2006 DA - 2006// TI - Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589 JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-05-1132 DO - 10.1158/1078-0432.CCR-05-1132 ID - Qian2006 ER - TY - JOUR AU - Chobanian, N. H. AU - Greenberg, V. L. AU - Gass, J. M. AU - Desimone, C. P. AU - Nagell, J. R. AU - Zimmer, S. G. PY - 2004 DA - 2004// TI - Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status JO - Anticancer Res VL - 24 ID - Chobanian2004 ER - TY - JOUR AU - Ganai, S. A. PY - 2016 DA - 2016// TI - Panobinostat: the small molecule metalloenzyme inhibitor with marvelous anticancer activity JO - Curr Top Med Chem VL - 16 UR - https://doi.org/10.2174/1568026615666150813145800 DO - 10.2174/1568026615666150813145800 ID - Ganai2016 ER - TY - JOUR AU - Chao, H. AU - Wang, L. AU - Hao, J. AU - Ni, J. AU - Chang, L. AU - Graham, P. H. PY - 2013 DA - 2013// TI - Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro JO - Cancer Lett VL - 329 UR - https://doi.org/10.1016/j.canlet.2012.08.035 DO - 10.1016/j.canlet.2012.08.035 ID - Chao2013 ER - TY - STD TI - Liffers K, Kolbe K, Westphal M, Lamszus K, Schulte A. Histone deacetylase inhibitors resensitize EGFR/EGFRvIII-overexpressing, erlotinib-resistant glioblastoma cells to tyrosine kinase inhibition. Target Oncol. 2015. [Epub ahead of print]. ID - ref58 ER - TY - JOUR AU - Schech, A. AU - Kazi, A. AU - Yu, S. AU - Shah, P. AU - Sabnis, G. PY - 2015 DA - 2015// TI - Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells JO - Mol Cancer Ther VL - 14 UR - https://doi.org/10.1158/1535-7163.MCT-14-0778 DO - 10.1158/1535-7163.MCT-14-0778 ID - Schech2015 ER -